Dirk Rades1, Trang Nguyen2, Steven E Schild3. 1. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany rades.dirk@gmx.net. 2. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany. 3. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
Abstract
BACKGROUND/AIM: Outcomes of elderly patients with cerebral metastases from kidney cancer may be improved by personalized treatment. A scoring instrument for estimating survival in these patients is presented. PATIENTS AND METHODS: Twenty-four elderly kidney cancer patients receiving whole-brain irradiation (WBI) were retrospectively investigated. WBI-regimen and six pre-treatment factors were evaluated including age, gender, performance score, number of cerebral metastases, extracranial metastases and time from kidney cancer diagnosis to WBI. RESULTS: Number of cerebral metastases (p=0.194) and time from kidney cancer diagnosis to WBI (p=0.107) correlated with survival and were included in the instrument. Based on these factors, patient scores of 0, 1 and 2 points resulted in 6-month survival rates of 0%, 15% and 60% (p=0.131), respectively. Two groups were designed, 0-1 and 2 points, with 6-month survival rates of 11% and 60% (p=0.108), respectively. CONCLUSION: This new instrument can assist physicians aiming to estimate a patient's survival prognosis to provide personalized treatment. Copyright
BACKGROUND/AIM: Outcomes of elderly patients with cerebral metastases from kidney cancer may be improved by personalized treatment. A scoring instrument for estimating survival in these patients is presented. PATIENTS AND METHODS: Twenty-four elderly kidney cancerpatients receiving whole-brain irradiation (WBI) were retrospectively investigated. WBI-regimen and six pre-treatment factors were evaluated including age, gender, performance score, number of cerebral metastases, extracranial metastases and time from kidney cancer diagnosis to WBI. RESULTS: Number of cerebral metastases (p=0.194) and time from kidney cancer diagnosis to WBI (p=0.107) correlated with survival and were included in the instrument. Based on these factors, patient scores of 0, 1 and 2 points resulted in 6-month survival rates of 0%, 15% and 60% (p=0.131), respectively. Two groups were designed, 0-1 and 2 points, with 6-month survival rates of 11% and 60% (p=0.108), respectively. CONCLUSION: This new instrument can assist physicians aiming to estimate a patient's survival prognosis to provide personalized treatment. Copyright
Authors: Regina M Hillebrand; Annabelle Vogt; Christian P Strassburg; Maria A Gonzalez-Carmona; Ingo G H Schmidt-Wolf Journal: Anticancer Res Date: 2019-09 Impact factor: 2.480
Authors: Jasmin N Evers; Steven E Schild; Barbara Segedin; Viorica Nagy; Mai Trong Khoa; Ngo Thuy Trang; Dirk Rades Journal: Anticancer Res Date: 2014-05 Impact factor: 2.480
Authors: May N Tsao; Dirk Rades; Andrew Wirth; Simon S Lo; Brita L Danielson; Laurie E Gaspar; Paul W Sperduto; Michael A Vogelbaum; Jeffrey D Radawski; Jian Z Wang; Michael T Gillin; Najeeb Mohideen; Carol A Hahn; Eric L Chang Journal: Pract Radiat Oncol Date: 2012-01-30